Jean Boulle Medtech Ltd. is active as an investor in early-stage medical technologies, with a particular track record in the development of medical devices for use in cardiology.

As lead investor, Jean Boulle Medtech has repeatedly attracted significant co-investment to help develop devices which save or improve quality of life.

By building scientific teams and undertaking clinical trials, new devices are developed successfully to be commercially viable. Thereafter, they are typically acquired by multinational medical devices and health care companies.

null
Tendyne Holdings – Jean Boulle Medtech was the founding investor in Tendyne Holdings, Inc. which developed one of the most promising Transcatheter mitral valve implant devices in existence today. Implanted in a beating heart, the Tendyne™ valve enables a significantly less invasive procedure to mitral valve treatment than open heart surgery. In September 2015 the Jean Boulle Group announced that Abbott Laboratories (NYSE: ABT) acquired Tendyne™ from Boulle Medtech and others for US$250 million in cash plus future payments tied to regulatory milestones.
null
VDYNE LLC – Jean Boulle Medtech founded VDYNE, a medical device company focused on developing transcatheter replacement valves to treat patients suffering from tricuspid regurgitation.